Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.

BACKGROUND Chromogranin A (CgA) is the neuroendocrine (NE) marker most frequently employed in detecting NE differentiation in prostate cancer patients, either at the tissue level or in the general circulation. METHODS We compared the two commercially CgA assay kits in detecting NE differentiation, in benign hyperplasia (BPH) or prostate cancer (PC) patients (pts). 170 pts with BPH, 107 with BPH+inflammation, and 136 PC pts entered the study. CgA was measured in each patient with the immunoradiometric assay (IRMA) and with the enzyme-linked immunoabsorbent assay (ELISA). RESULTS A moderate relationship was found between CgA measured with IRMA and ELISA in the whole population (Spearman's R=0.65, p<0.05), in BPH pts (R=0.76, p<0.05), in BPH+inflammation pts (R=0.53, p<0.05) and in PC pts (R=0.60, p<0.05). Twenty-two out of 62 pts (35.4%) with elevated ELISA CgA did not have increased IRMA CgA; by contrast, 21/61 pts (34.4%) with elevated IRMA CgA were not recognized as abnormal by the ELISA kit. CONCLUSIONS CgA measured by the two assays provided a significant discordance rate, suggesting that the two kits might elicit different information.

[1]  K. Akakura,et al.  Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. , 2005, European urology.

[2]  O. Cussenot,et al.  Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. , 1996, The Journal of urology.

[3]  P. Scardino,et al.  National Comprehensive Cancer Network guidelines for the management of prostate cancer. , 2003, Urology.

[4]  L. Dillen,et al.  Enzyme-linked immunosorbent assay for chromogranin A. , 1989, Clinical Chemistry.

[5]  L. Dogliotti,et al.  Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.

[6]  C. Supuran,et al.  Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.

[7]  D. Pons-Anicet,et al.  A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245) , 1999, British Journal of Cancer.

[8]  P. Kantoff,et al.  Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. , 2005, Urology.

[9]  L. Dogliotti,et al.  Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.

[10]  D. O'Connor,et al.  The chromogranin-secretogranin family. , 2003, The New England journal of medicine.

[11]  R. Bouillon,et al.  Chromogranin A: its clinical value as marker of neuroendocrine tumours , 1998, European journal of clinical investigation.

[12]  T. H. van der Kwast,et al.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. , 1999, The American journal of pathology.

[13]  S. Cresta,et al.  Chromogranin a Measurement in Neuroendocrine Tumors , 1998, The International journal of biological markers.

[14]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[15]  F. D. De Braud,et al.  Comparison between Two Methods in the Determination of Circulating Chromogranin A in Neuroendocrine Tumors (NETs): Results of a Prospective Multicenter Observational Study , 2005 .

[16]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Stridsberg,et al.  A comparison between three commercial kits for chromogranin A measurements. , 2003, The Journal of endocrinology.

[18]  G. Lucignani,et al.  Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. , 2004, The International journal of biological markers.

[19]  P. Abrahamsson,et al.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.

[20]  P. Abrahamsson.  Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.

[21]  S. Fosså,et al.  Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer , 2001, The Prostate.

[22]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[23]  M. Stridsberg.  Measurements of chromogranins and chromogranin-related peptides by immunological methods. , 2000, Advances in experimental medicine and biology.

[24]  S. Monti,et al.  Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma , 2003, The Prostate.

[25]  L. Dogliotti,et al.  Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.